A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps
Key facts
- Who runs it
- Keymed Biosciences Co.Ltd
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 1/2
- People taking part
- 88 people enrolled
- Started
- 11 Jul 2022
- Ended
- 29 Mar 2024
- Type of study
- Interventional, 4 groups
- Treatments tested
- CM326
- Placebo
- Record updated
- 8 November 2024
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Subjects who are capable of understanding the nature of the study and voluntarily signing the ICF
- Male or female subjects, aged between 18 and 70 years old (inclusive), with a body mass index (BMI) ≥ 19 kg/m2
- Diagnosed with Chronic Rhinosinusitis With Nasal Polyps
- The total NPS score should be at least 3 points, with at least 1 point in each side of the nasal cavity
- Prior treatment with systemic corticosteroids (SCS) within two years before screening, and/or contraindicate to or intolerance to systemic corticosteroids, and/or with prior surgery to nasal polyps 6 months before the screening
- Ongoing symptoms for at least 4 weeks before screening:1) Nasal congestion/obstruction; 2) Other symptom, e.g., loss of smell or rhinorrhea
Who cannot take part
- Have used of systemic immunosuppressants for inflammatory or autoimmune diseases within 8 weeks or 5 half-lives prior to randomization
- Have initiated leukotriene receptor antagonist therapy within 4 weeks prior to randomization
- have received allergen-specific immunotherapy that initiated within 3 months prior to randomization or planned to be initiated during the study period
- Have undergone nasal surgery (including nasal polypectomy) within 6 months prior to screening
- Have received medium- and short-acting systemic corticosteroids (including oral, intravenous, intramuscular corticosteroids), nasal dripping corticosteroids, traditional Chinese medicine (including systemic and local herbal products preparations) for chronic rhinosinusitis (CRS) within 4 weeks prior to screening, or long-acting systemic corticosteroids
- With concomitant asthma (including suspected diagnosis of asthma) will be excluded if they meet the following conditions: predicted FEV1 of≤ 60%, or acute exacerbation of asthma within 3 months prior to screening requiring SCS or hospitalization (> 24 hours), or using inhaled corticosteroids (ICS) of > 1000 μg fluticasone propionate or others at equivalent doses
- Have received live attenuated vaccines within 12 weeks prior to randomization, or during the planned study; or have received inactivated vaccines (e.g., novel coronavirus vaccines) within 30 days prior to randomization
- With a history of large alcohol consumption or a history of drug abuse within 3 months prior to screening
- Allergic or intolerant to mometasone furoate spray or CM326/placebo
- With allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener's granulomatosis), Young's syndrome, Kartagener's syndrome or other dyskinetic ciliary syndromes, cystic fibrosis
- With acute sinusitis, nasal infection, or upper respiratory tract infection at screening
- Have symptoms or whose CT scan suggests allergic fungal sinusitis
- With malignant or benign neoplasm of nasal cavities
- With other uncontrolled serious diseases or recurrent chronic diseases
- Have severe hepatic and renal impairment
- With known or suspected immunosuppression, including, but not limited to, the history of invasive opportunistic infections
- With other medical or non-medical conditions that are not suitable for participation in the study in the opinion of the investigator
- With antrochoanal polyps
- With severe deviation of the nasal septum occludes at least one nostril
- With persistent rhinitis medicamentosas
- Subjects who are pregnant or planning to become pregnant, or breastfeeding during the study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multi-center, randomized, double blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of CM326 in patients with chronic rhinosinusitis with nasal polyps.
The 4 groups in the trial
- Group 1: 55mg Q2WTreatment being tested
CM326 55 mg or matched placebo, every 2 weeks, subcutaneous (SC)
Treatment: CM326 and Placebo
- Group 2: 110mg Q2WTreatment being tested
CM326 110 mg or matched placebo, every 2 weeks, subcutaneous (SC)
Treatment: CM326 and Placebo
- Group 3: 220mg Q2WTreatment being tested
CM326 220 mg or matched placebo, every 2 weeks, subcutaneous (SC)
Treatment: CM326 and Placebo
- Group 4: 220mg Q4WTreatment being tested
CM326 220mg or matched placebo, every 4 weeks, subcutaneous (SC)
Treatment: CM326 and Placebo
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double Blind, Placebo-controlled, Dose Escalation Phase 1b/2a Study to Evaluate the Safety, Tolerability, PK, PD, Immunogenicity and Preliminary Efficacy of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps
- Publications
- An anti-TSLP monoclonal antibody for uncontrolled CRSwNP: the DUBHE randomized clinical trial.Nature communications, 2025
- Anti-thymic stromal lymphopoietin monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps (DUBHE): Rationale and design of a multicenter, randomized, double-blind, placebo-controlled study.Asia Pacific allergy, 2024
- Record updated
- 8 November 2024